Commercial Alphabet’s health subsidiary Verily cuts staff by 15% in...

Alphabet’s health subsidiary Verily cuts staff by 15% in a bid to strategize and reorganize

-

In an email shared with Verily employees recently, the company CEO Stephen Gillett announced that they will be laying off 15% of the company’s more than 1,600 employees (approximately 240 people) in order to gain more financial independence from their parent company Alphabet, and to lay foundations for a broader strategy shift and reorganization.

The company aims to bridge the gap between research and care and move from multiple lines of business to one centralized product organization, so that healthcare solutions are increasingly interconnected.

The company’s plan is to focus its strategic efforts on becoming the evidence and data pioneer of precision health and this would mean that several of Verily’s portfolio products would be coming to an end. These include Verily Value Suite, a data-driven clinical and financial insights platform, and other early-stage products on remote patient monitoring for people suffering from heart diseases.

The company’s new operating model is also accompanied by several leadership changes, for example, Jordi Parramon, president of Verily’s devices business is expected to depart from the company sometime later this year and will be transitioning into an advisory capacity in the meantime. 

Other jobs have gained increased jurisdiction, job titles for Amy Abernethy, M.D., Ph.D., have been expanded to the president of product and chief medical officer, and Scott Burke who was previously working in the capacity of chief technology officer, will now also supervise the hardware engineering and devices team.

In the initial email that was sent out, staff was informed to work from home as Verily’s office would remain closed for the remainder of the week. Those employees that had been in the office at the time the email was sent out were instructed to return home, these instructions were also for staff embers who had been working out from Google Offices.

“While communicating via email is not ideal, this was a deliberate decision, enabling us to communicate as efficiently and simultaneously as possible. We’re also taking today and the rest of the week to ensure each impacted Veep (Verily employees) has a personal discussion with a leader and HR partner to discuss the details, answer questions, and provide support through the transition,” shared Gillett.

The company stated that its immediate priority is to give employees the necessary support to ease this transition. Severance, coaching, and outplacement services will be provided to employees in the coming months to help them.

Amidst a wave of industry layoffs and fear of recession, this is the first-ever known layoff to hit the Google parent company. Verily is one of Google’s sister companies that specializes in healthcare. It operates within Alphabet’s “Other Bets” category.

+ posts

Latest news

FDA and CDC exploring unlikely relation between COVID-19 vaccine and stroke

The FDA and CDC have brought out new revelations that the revised COVID-19 injection from Pfizer Inc...

Disappointing sales prompt AstraZeneca to pull out leukemia drug Lumoxiti from U.S. market

In a letter shared with healthcare providers, AstraZeneca has announced that it will be pulling its leukemia...

Sanofi’s Venture Capital units to receive over $750 million in investment to boost firm’s investment capabilities 

After a successful last year in which Sanofi Ventures made its second-highest number of deals, 10 rounds...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

Amgen’s KRAS drug gets early FDA approval for lung cancer with specific mutation

On Friday, the United States FDA (Food and Drug Administration) has authorized a medication of Amgen Biopharmaceutical in patients with NSCLC

You might also likeRELATED
Recommended to you